APP and amyloidosis: They crossed SIRT3−/− mice with APP/PSI mice (double-transgenic mouse models of AD expressing a chimeric mouse/human amyloid precursor protein and containing the L166P mutation, both directed to the CNS [67]) and generated APP/PS1/SIRT3−/− mice with metabolic syndrome and amyloid pathology.